Achieving a Higher pCR Rate With Nab-Paclitaxel in Breast Cancer
January 9th 2018Christian Jackisch, MD, PhD, Professor of Obstetrics and Gynecology and Head of the Department of Obsterics and Gynaecology, Sana Klinikum Offenbach in Germany, discusses results of the GeparSepto study, as well as how a higher pathologic complete response (pCR) rate is achieved with nab-paclitaxel (Abraxane) in breast cancer.
Watch
No Significant Efficacy Seen With Trastuzumab in HER2-Low Breast Cancer
January 9th 2018According to findings presented at the 2017 San Antonio Breast Cancer Symposium, no significant efficacy was seen in a trial to determine the value of trastuzumab plus standard adjuvant chemotherapy in patients with low levels of HER2 protein.
Read More
Ivosidenib Demonstrates Responses in More Than 40% in Relapsed/Refractory IDH+ AML
December 16th 2017Ivosidenib (AG-120), an IDH1 inhibitor, demonstrated an objective response rate (ORR) of 41.6% in patients with relapsed/refractory <em>IDH1</em>-mutant acute myeloid leukemia (AML), according to findings from a single-arm phase I study.
Read More
Pegylated Interferon Alfa-2a Active in Hydroxyurea-Resistant PV and ET
December 16th 2017Treatment with pegylated interferon alfa-2a led to objective responses in about two-thirds of patients with hydroxyurea (Hydrea)-resistant/intolerant polycythemia vera or high-risk essential thrombocytopenia, a phase II study of salvage therapy showed.
Read More
Sotatercept in Patients With MPN-Associated Myelofibrosis and Anemia
December 16th 2017Srdan Verstovsek, MD, of MD Anderson Cancer Center, discusses a study of sotatercept (ACE-011) alone and in combination with ruxolitinib in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia.
Watch
Ropeginterferon Alfa-2b Has Long-Term Benefits in Polycythemia Vera
December 15th 2017A novel pegylated formulation of interferon alfa-2b achieved a significantly higher rate of complete hematologic response compared with hydroxyurea (Hydrea) in patients with polycythemia vera, according to 2-year findings from the follow-up phase III CONTI-PV randomized trial.
Read More
Sotatercept Boosts Hemoglobin in MPN-Associated Myelofibrosis
December 15th 2017The investigational activin receptor IIA ligand trap sotatercept safely increases hemoglobin levels in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis, both when used alone and in combination with ruxolitinib (Jakafi).
Read More
Results and Impact of a Patient-Reported Symptoms Tool in Multiple Myeloma
December 14th 2017Joshua Richter, MD, Hackensack University Medical Center, discusses a tool which explored the incidence and survival impact of self-reported symptoms and psychologic distress among patients with multiple myeloma during the 2017 ASH Annual Meeting.
Watch
Daratumumab (Darzalex) in combination with VMP (bortezomib [Velcade], melphalan, and prednisone) could become a new standard of care for patients with newly diagnosed multiple myeloma who are unable to undergo transplant following findings from the phase III ALCYONE study.
Read More
Maintenance Therapy With Elotuzumab/Lenalidomide Boosts Response Conversions in Multiple Myeloma
December 14th 2017Following autologous stem cell transplant (ASCT) for patients with multiple myeloma, maintenance therapy of elotuzumab (Empliciti) in combination with lenalidomide (Revlimid) led to an increased rate of response conversions from prior induction therapy, according to the results of a phase II study.
Read More
ASPIRE Trial Confirms Survival Benefit in Myeloma for Carfilzomib Plus Lenalidomide/Dexamethasone
December 14th 2017In the final analysis of the phase III ASPIRE trial, an improvement in survival was confirmed with the combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone for patients with relapsed/refractory multiple myeloma, according to findings presented at the 2017 ASH Annual Meeting.
Read More
Results for the Combination of Selinexor and Daratumumab in Multiple Myeloma
December 14th 2017Cristina Gasparetto, MD, associate professor, head of the myeloma program, Duke University Medical Center, discusses a phase 1b study to assess the combination of selinexor and daratumumab in patients with relapsed/refractory multiple myeloma previously exposed to proteasome inhibitors and immunomodulatory drugs during the 2017 ASH Annual Meeting.
Watch
Lasting Responses Seen With Daratumumab in Smoldering Multiple Myeloma
December 13th 2017In findings from the phase II CENTAURUS clinical trial, treatment with daratumumab (Darzalex) monotherapy produced lasting responses in patients with intermediate- and high-risk smoldering multiple myeloma (SMM).
Read More
Thorough Treatment Approach Demonstrates Encouraging Responses in Smoldering Multiple Myeloma
December 13th 2017A novel approach to treatment for patients with smoldering multiple myeloma demonstrated a high rate of complete responses, according to a study presented at the 2017 ASH Annual Meeting. The single-arm, phase II trial evaluated a strategy using induction therapy with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone followed by high-dose therapy and autologous stem cell transplantation, consolidation therapy and then maintenance therapy with lenalidomide and dexamethasone.
Read More
Exciting Response Rates Seen in Updates Findings of bb2121 in Multiple Myeloma
December 13th 2017Chimeric antigen receptor T-cell therapy with bb2121 demonstrated an objective response rate of 94% in patients with relapsed/refractory multiple myeloma, according to findings from a dose-escalation study. The senior study author, James N. Kochenderfer, MD, presented updated findings from the study during the 2017 ASH Annual Meeting, and commented that 89% of patients had a very good partial response or better, and 56% of patients had a complete remission. <br />
Read More
The Safety and Efficacy of Venetoclax/Obinutuzumab Combo in CLL
December 13th 2017Ian Flinn, MD, Director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the safety, efficacy, and MRD negativity of a combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.<br />
Watch
Brentuximab Vedotin/Nivolumab Combo Promising for Relapsed/Refractory Hodgkin Lymphoma
December 13th 2017The combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) demonstrated promising clinical activity in patients with relapsed/refractory Hodgkin lymphoma, according to results from a phase I/II trial presented at the 2017 ASH Annual Meeting.
Read More
Cemiplimab Monotherapy Induces 50% ORR in Hodgkin Lymphoma
December 13th 2017Treatment with the novel PD-1 inhibitor cemiplimab induced responses in half of the patients with Hodgkin lymphoma in a phase I study of patients with B-lymphoid malignancies; among patients with B-cell non-Hodgkin lymphoma treated with the monotherapy, the overall response rate was 11.1%, according to a poster presentation at the 2017 ASH Annual Meeting.
Read More
Impressive Responses Seen With Tisagenlecleucel in DLBCL in JULIET Trial
December 13th 2017Treatment with tisagenlecleucel (Kymriah) continues to excite the possibilities seen with chimeric antigen receptor T-cell therapy with impressive responses seen with the therapy in patients with relapsed/refractory diffuse large B-cell lymphoma. In the phase II JULIET trial, an overall response rate of 53.1% was observed, according to findings presented at the ASH Annual Meeting.
Read More
Phase I Trial Demonstrates Activity of Antibody-Drug Conjugate Targeting LIV-1 in TNBC
December 13th 2017Treatment with ladiratuzumab vedotin demonstrated an estimated median progression-free survival (PFS) of 11.6 weeks for patients with heavily pretreated metastatic triple-negative breast cancer (TNBC) treated with the recommended phase II dose of the antibody–drug conjugate, according to results of a phase I study presented during the 2017 San Antonio Breast Cancer Symposium.
Read More
5-Year Follow-Up of CALGB 40502 Study in TNBC
December 13th 2017Hope S. Rugo, MD, professor of medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the 5-year follow-up of the CALGB 40502 study for patients with triple-negative breast cancer (TNBC).
Watch
OlympiAD Trial Demonstrates Acceptable Toxicity Profile for Olaparib in BRCA+, HER2- Breast Cancer
December 13th 2017Treatment discontinuation due to toxicity was less frequent with olaparib (Lynparza) monotherapy compared with chemotherapy in patients with HER2-negative metastatic breast cancer and a germline <em>BRCA</em> mutation in the phase III OlympiAD study.
Read More
Follow-Up Results for Ruxolitinib in the Second-Line Treatment of PV
December 12th 2017Ruben A. Mesa, MD, Director of the UT Health San Antonio Cancer Center, discusses 4-year follow-up results from the phase III RESPONSE trial, which investigated ruxolitinib (Jafaki) with best available therapy for the treatment of polycythemia vera (PV) during the 2017 ASH Annual Meeting.
Watch
Rituximab Added to Ibrutinib in CLL Shows No Improvement In PFS, OS
December 12th 2017Adding rituximab (Rituxan) to ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL) did not improve progression-free survival (PFS) or overall survival (OS) versus ibrutinib alone, despite there being a faster time to complete remission.
Read More
Frontline Atezolizumab Triplet Shows Promising Response Rates in Follicular Lymphoma
December 12th 2017According to results of a phase Ib/II trial presented at the 2017 ASH Annual Meeting, the frontline triplet regimen of atezolizumab (Tecentriq), obinutuzumab (Gazyva), and bendamustine was associated with an overall response rate (ORR) of 85% (Modified Lugano criteria; independent review) in patients with follicular lymphoma.
Read More
Dr. Berdeja Discusses Results for bb2121 in Multiple Myeloma
December 12th 2017Jesus Berdeja, MD, Director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses results of a study that explored bb2121, an anti-BCMA CAR T cell therapy, in heavily pretreated patients with relapsed/refractory multiple myeloma during the 2017 ASH Annual Meeting.
Watch
Liso-Cel Shows Potent, Durable Remissions in High-Risk DLBCL
December 12th 2017Updated results from the TRANSCEND study demonstrated that liso-cel (lisocabtagene maraleucel), formally known as JCAR017, induced an 81% objective response rate and a 63% complete remission rate in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
High Response Rate Seen With Ibrutinib/Venetoclax in Relapsed/Refractory CLL
December 12th 2017In patients with relapsed/refractory chronic lymphocytic leukemia (CLL), ibrutinib (Imbruvica) in combination with venetoclax (Venclexta) induced an objective response rate (ORR) of 100%, according to findings from the TAP CLARITY clinical trial.
Read More
BLU-285 Induces Responses in Patients With Systemic Mastocytosis
December 11th 2017Treatment using BLU-285 (Avapritinib) induced clinically significant activity in patients with an advanced or aggressive form of systemic mastocytosis (ASM), a rare blood disorder that originates in mast cells, according to data from an ongoing phase I trial.<br />
Read More